Signal Breakdown
5 verified publisher articles from recent coverage.
Limited TV coverage this week.
Limited video coverage this week.
GDELT tone + context across verified sources.
What’s Driving Sentiment
Bullish Signals
- IDEXX reported Q2 revenue above expectations and raised full-year 2026 revenue guidance.
- The company is expanding diagnostic tests and imaging systems, driving stronger recurring testing demand across its installed base.
- Analyst notes and bullish write-ups cite the guidance raise and product expansion as catalysts for earnings growth.
- Wall Street consensus expects earnings growth next week, keeping investor focus on EPS, revenue and guidance confirmation.
Risk Factors
- Robeco cut its IDXX stake by 38% in Q3, selling 65,562 shares, which signals notable institutional selling pressure.
- IDEXX trades at elevated multiples with a trailing P/E of 36.65 and forward P/E of 31.45, which could limit upside if growth slows.
- High street expectations for upcoming earnings create execution risk if reported EPS, revenue or guidance fall short.
Evidence
- 2026-10-26Source: TIINGO
Summary: Idexx Laboratories (IDXX) will report earnings next week; Wall Street expects earnings growth, signaling positive consensus sentiment. Investors should watch reported EPS, revenue and management guidance for confirmation.
Bullish - 2026-10-23Source: TIINGO
Summary: IDEXX reported Q2 revenue above expectations and raised full-year 2026 revenue guidance while expanding diagnostic tests and imaging systems, signaling stronger recurring testing demand across its installed base and a positive outlook for growth.
Bullish - 2026-10-23Source: TIINGO
Summary: Robeco Institutional Asset Management cut its IDXX stake by 38% in Q3, selling 65,562 shares and holding 106,831 shares per a 13F filing, indicating notable institutional selling pressure though not conclusive about Idexx's fundamentals.
Bearish - 2026-10-22Source: GDELT
Summary: IDEXX has raised guidance and is expanding its product lineup; Insider Monkey compares IDXX to ZTS and NEOG and asks whether these factors can sustain additional earnings growth.
Bullish - 2026-10-22Source: TIINGO
Summary: IDEXX Laboratories traded at $553.48 on Oct 21, 2026; trailing P/E 36.65, forward P/E 31.45. Astute Optics presents a bullish thesis citing raised guidance and product expansion driving earnings growth, comparing IDXX to peers ZTS and NEOG.
Bullish
Showing 5 of 5 verified news articles
- No current evidence is available for this source.
No current verified Archive TV segments
- No current evidence is available for this source.
No verified video evidence in the current 7-day window
Formula & Methodology
- News
- GDELT discovers coverage; only publisher passages that directly name the company qualify as news evidence.
- TV
- Internet Archive TV captions are retained only with a match-centered quote that directly names the company.
- Video
- Recent Bullish Gator videos tagged to the company; the item summary and publisher label feed the judge.
- Holistic AI judge
- A single Azure OpenAI call reads the news, television, and video evidence together and returns the rating, a 0–100 composite, and a short rationale. Thresholds are enum-only: 65+ Bullish, 35 or lower Bearish, Neutral in between.
Data Source
News evidence comes from the GDELT Global Knowledge Graph (via BigQuery); TV evidence from the Internet Archive TV News Archive; video evidence from recent Bullish Gator video coverage. Azure OpenAI filters per-article relevance and serves as the holistic AI judge that produces the composite rating. Portions use data from The GDELT Project under open data terms. This page is informational analysis, not investment advice. See Financial Disclaimer.